Cagent Vascular Receives Investment to Support Commercialization of Serranator BTK Catheter

June 17, 2021—Cagent Vascular Inc. announced an investment of $9 million by Sectoral Asset Management, which Cagent will use to accelerate the commercialization and scaling of manufacturing for its Serranator below-the-knee (BTK) percutaneous transluminal angioplasty (PTA) serration balloon catheter. Further uses of the proceeds include expanding the product offering to include larger sizes to treat above-the-knee arteries.

With the investment, Marc-Andre Marcotte, Partner and Chief Operating Officer at Sectoral, has joined Cagent Vascular’s board of directors.

According to Cagent Vascular, the Serranator device features serrated metal strips embedded on a semicompliant balloon. It is designed to create multiple longitudinal lines of interrupted microserrations within the luminal surface to aid in arterial expansion and provide predictable and controlled lumen gain using low atmospheres of pressure.

On February 1, 2021, the company announced the presentation of results from its PRELUDE-BTK study of the Serranator technology, which received FDA 510(k) clearance for the BTK indication in 2020.

The Serranator PTA balloon catheter for the infrapopliteal indication is currently available in 2.5-, 3-, 3.5-mm balloon diameters and 40-, 80-, and 120-mm balloon lengths, advised Cagent Vascular.

Sarang Mangalmurti, MD, an interventional cardiologist at Bryn Mawr Hospital in Bryn Mawr, Pennsylvania, commented in the company’s press release, “The BTK space is in desperate need of innovation. These vessels are more challenging in terms of size, lesion length, and calcification and non–drug-based balloon angioplasty is still the primary treatment. My experience with Serranator has been excellent and with its novel mechanism of action it has become an important tool in treating BTK disease. In the near future, I look forward to using this technology in vessels above the knee to further optimize my angioplasty results.”